Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents

Prion diseases such as Creutzfeldt–Jakob disease (CJD) are incurable and rapidly fatal neurodegenerative diseases. Because prion protein (PrP) is necessary for prion replication but dispensable for the host, we developed the PrP–FRET-enabled high throughput assay (PrP–FEHTA) to screen for compounds...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Proceedings of the National Academy of Sciences - PNAS 2013-04, Vol.110 (17), p.7044-7049
Hauptverfasser:	Karapetyan, Yervand Eduard, Sferrazza, Gian Franco, Zhou, Minghai, Ottenberg, Gregory, Spicer, Timothy, Chase, Peter, Fallahi, Mohammad, Hodder, Peter, Weissmann, Charles, Lasmézas, Corinne Ida
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies Astemizole - pharmacology Astemizole - therapeutic use autophagy Autophagy - drug effects Biological and medical sciences Biological Sciences blood-brain barrier Blotting, Western Cell Line, Tumor Cells Creutzfeldt Jakob syndrome Creutzfeldt-Jakob disease Drug Discovery - methods Drug Evaluation, Preclinical - methods Drugs Fluorescence Resonance Energy Transfer - methods Fundamental and applied biological sciences. Psychology Gene expression hay fever High-Throughput Screening Assays - methods Humans Infections Kaplan-Meier Estimate mechanism of action Medical treatment Mice Mice, Inbred C57BL Nervous system diseases Neurodegenerative diseases Neurons patients pharmacology Preclinical drug evaluation Prion diseases Prion Diseases - drug therapy Prions Prions - metabolism R&D Research & development Reverse Transcriptase Polymerase Chain Reaction screening tacrolimus Tacrolimus - pharmacology therapeutics Vertebrates: nervous system and sense organs
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!